z-logo
open-access-imgOpen Access
Prominent proliferative response of peripheral blood mononuclear cells to a recombinant non‐structural (NS3) protein of hepatitis C virus in patients with chronic hepatitis C
Author(s) -
YANG P.M.,
HWANG L.H.,
LAI M.Y.,
HUANG W.L.,
CHU Y.D.,
CHI W.K.,
CHIANG B.L.,
KAO J.H.,
CHEN P.J.,
CHEN D.S.
Publication year - 1995
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1995.tb08350.x
Subject(s) - hepatitis c virus , peripheral blood mononuclear cell , ns3 , immunology , medicine , hepatitis c , hepatitis , immune system , virology , recombinant dna , antigen , virus , biology , in vitro , biochemistry , gene
SUMMARY The proliferative response of peripheral blood mononuclear cells (PBMC) to a recombinant non‐structural (NS3) protein of hepatitis C virus (HCV) was studied in 41 patients with chronic hepatitis C. Of them, 28 had chronic persistent hepatitis (CPH) and 13 chronic active hepatitis (CAH). The positive proliferation rate of PBMC to the recombinant NS3 protein, T9Ag, was 66% in the 41 patients (77% in CAH versus 61 % in CPH; P > 0·05) when stimulation index (SI) = 4 was set as the cut‐off value. However, mean SI of CAH patients was significantly higher than that of CPH patients (8·3 ± 5·2 versus 5·1 ± 3·6; P < 0·05). Six other chronic hepatitis patients who were repeatedly negative for anti‐HCV antibody but positive for serum HCV RNA also had an SI of ≥ 4·0. The frequency of cellular immune response to the T9Ag is among the highest results obtained by using HCV antigens tested so far. Our studies thus indicate that NS3 is an immunologically important region of HCV for T cells. Moreover, the proliferative response to T9Ag may help to establish hepatitis C etiology in chronic hepatitis patients who are seronegative with currently available anti‐HCV assays.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here